Christopher Moxham
Vorstandsvorsitzender bei Rarebase, PBC
Profil
Dr. Christopher Moxham is a Chief Executive & Scientific Officer at Transcripta Bio, Inc. and a President & Chief Executive Officer at Rarebase, PBC.
Dr. Moxham was previously employed as a Chief Scientific Officer by Fulcrum Therapeutics, Inc. and a Head-Drug Discovery by Eli Lilly & Co.
He received his undergraduate degree from Cornell University and a doctorate degree from Stony Brook University.
Aktive Positionen von Christopher Moxham
Unternehmen | Position | Beginn |
---|---|---|
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Vorstandsvorsitzender | 04.10.2023 |
Ehemalige bekannte Positionen von Christopher Moxham
Unternehmen | Position | Ende |
---|---|---|
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
FULCRUM THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Christopher Moxham
Cornell University | Undergraduate Degree |
Stony Brook University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
FULCRUM THERAPEUTICS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Private Unternehmen | 1 |
---|---|
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Technology Services |